The effect of GLP- 1 together with GIP on food intake, body weight, and locomotor activity was determined following intracerebroventricular (ICV) administration of GLP- 1 and/or GIP in mice
doi:10.2174/138955706777698688
Clinical trial data suggests comparable GI side effect profiles, though some patients who cannot tolerate one medication do better on the other due to individual receptor sensitivity differences
Peptides can provide targeted effects with fewer systemic side effects but frequently still lack randomized large trials
[PubMed] [Google Scholar] 44.Yamamoto O, Yoshinaga K, Asahi M, Murata I
Other at-risk patients include the elderly, people with digestive tract problems, and people taking certain long-term medications for heartburn or diabetes